Login to Your Account



Selinexor inexorable? Bid in AML falters phase II; multiple efforts continue

By Randy Osborne
Staff Writer

Thursday, March 2, 2017

Karyopharm Therapeutics Inc.'s phase II failure with lowered-dose selinexor in AML "put[s] to rest the sepsis question," which was "a big overhang on the stock, frankly, and on the drug," noted CEO Michael Kauffman.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription